See more : Soyea Technology Co., Ltd (000909.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of LifeMD, Inc. (LFMDP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LifeMD, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Eastwood Bio-Medical Canada Inc. (EWOOF) Income Statement Analysis – Financial Results
- Sitka Gold Corp. (SIG.CN) Income Statement Analysis – Financial Results
- Molina Healthcare, Inc. (MOH) Income Statement Analysis – Financial Results
- SUTIMCo International, Inc. (SUTI) Income Statement Analysis – Financial Results
- Kobayashi Yoko Co., Ltd. (8742.T) Income Statement Analysis – Financial Results
LifeMD, Inc. (LFMDP)
About LifeMD, Inc.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152.55M | 119.03M | 92.88M | 37.29M | 12.47M | 8.32M | 5.05M | 5.24M | 1.22M | 714.16K | 808.36K | 673.78K | 743.83K |
| Cost of Revenue | 18.90M | 18.67M | 18.00M | 8.91M | 3.27M | 1.97M | 1.48M | 1.95M | 247.77K | 172.85K | 181.30K | 125.62K | 241.26K |
| Gross Profit | 133.65M | 100.37M | 74.88M | 28.39M | 9.20M | 6.36M | 3.57M | 3.29M | 971.09K | 541.31K | 627.06K | 548.16K | 502.56K |
| Gross Profit Ratio | 87.61% | 84.32% | 80.62% | 76.12% | 73.77% | 76.35% | 70.65% | 62.85% | 79.67% | 75.80% | 77.57% | 81.36% | 67.56% |
| Research & Development | 6.06M | 2.97M | 778.77K | 446.75K | 222.88K | 120.54K | 0.00 | 0.00 | 23.93K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 51.69M | 46.96M | 39.57M | 42.21M | 2.40M | 3.33M | 2.98M | 2.76M | 978.72K | 1.07M | 1.17M | 1.09M | 1.08M |
| Selling & Marketing | 76.45M | 78.37M | 82.54M | 41.67M | 8.17M | 5.08M | 1.66M | 1.71M | 230.66K | 57.25K | 0.00 | 0.00 | 0.00 |
| SG&A | 128.15M | 125.33M | 122.11M | 83.88M | 10.57M | 8.41M | 4.64M | 4.47M | 1.21M | 1.07M | 1.17M | 1.09M | 1.08M |
| Other Expenses | 13.93M | 11.75M | 6.29M | 1.88M | 1.30M | -516.98K | 215.13K | 0.00 | 0.00 | 57.88K | 54.33K | 80.55K | 77.50K |
| Operating Expenses | 148.46M | 140.05M | 129.18M | 86.21M | 12.09M | 8.41M | 4.64M | 4.47M | 1.23M | 1.07M | 1.17M | 1.09M | 1.08M |
| Cost & Expenses | 167.04M | 158.72M | 147.18M | 95.11M | 15.36M | 10.38M | 6.12M | 6.41M | 1.48M | 1.25M | 1.35M | 1.21M | 1.32M |
| Interest Income | 0.00 | 1.28M | 3.02M | 1.67M | 761.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.60M | 1.28M | 3.02M | 1.67M | 761.15K | 354.39K | 100.52K | 48.61K | 37.48K | 4.68K | 3.39K | 3.37K | 21.26K |
| Depreciation & Amortization | 6.60M | 3.77M | 868.76K | 397.77K | 335.61K | 195.78K | 1.23M | 43.75K | 43.75K | 56.98K | 56.97K | 56.97K | 56.69K |
| EBITDA | -8.21M | -39.61M | -53.95M | -57.48M | -2.55M | -1.86M | -138.43K | -1.17M | -91.21K | -416.02K | -225.10K | -402.50K | -442.18K |
| EBITDA Ratio | -5.38% | -27.07% | -53.23% | -155.04% | -20.48% | -11.23% | -21.12% | -22.42% | -17.92% | -66.36% | -60.55% | -71.69% | -69.87% |
| Operating Income | -14.49M | -39.69M | -54.30M | -57.82M | -2.89M | -2.06M | -1.07M | -1.17M | -262.22K | -530.88K | -546.41K | -540.03K | -576.37K |
| Operating Income Ratio | -9.50% | -33.34% | -58.47% | -155.04% | -23.18% | -24.70% | -21.12% | -22.42% | -21.51% | -74.34% | -67.59% | -80.15% | -77.49% |
| Total Other Income/Expenses | -2.92M | -4.97M | -7.02M | -2.58M | -761.15K | -354.39K | -150.92K | -48.61K | 89.79K | 53.19K | 260.95K | 77.18K | 56.24K |
| Income Before Tax | -17.41M | -44.66M | -61.32M | -60.40M | -3.65M | -1.48M | -1.22M | -1.22M | -172.43K | -477.69K | -285.46K | -462.85K | -520.13K |
| Income Before Tax Ratio | -11.41% | -37.52% | -66.02% | -161.96% | -29.28% | -17.84% | -24.11% | -23.35% | -14.15% | -66.89% | -35.31% | -68.69% | -69.93% |
| Income Tax Expense | 428.00K | 360.70K | 7.70K | 122.50K | -122.50K | -124.70K | -12.49K | -115.75K | -13.20K | -17.20K | -17.20K | -17.20K | -17.20K |
| Net Income | -20.60M | -45.02M | -61.32M | -60.52M | -3.53M | -1.24M | -1.21M | -1.11M | -61.99K | -460.49K | -268.26K | -445.65K | -502.93K |
| Net Income Ratio | -13.50% | -37.82% | -66.03% | -162.29% | -28.30% | -14.91% | -23.86% | -21.14% | -5.09% | -64.48% | -33.19% | -66.14% | -67.61% |
| EPS | -0.70 | -1.45 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.08 | -0.05 | -0.08 | -0.07 |
| EPS Diluted | -0.70 | -1.45 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.07 | -0.04 | -0.08 | -0.07 |
| Weighted Avg Shares Out | 33.91M | 30.98M | 27.01M | 14.28M | 9.90M | 8.84M | 8.80M | 7.05M | 6.16M | 6.07M | 5.88M | 5.50M | 7.52M |
| Weighted Avg Shares Out (Dil) | 33.91M | 30.98M | 27.01M | 14.28M | 9.90M | 9.05M | 8.80M | 7.05M | 6.40M | 6.15M | 6.02M | 5.78M | 7.52M |
LifeMD Reports Second Quarter 2023 Results; Achieves Positive Free Cash Flow and Raises 2023 Revenue Guidance
LifeMD to Report Second Quarter 2023 Financial Results on August 9
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD Elevates Successful GLP-1 Weight Management Program with Proprietary Platform Enhancements
LifeMD's Turnaround Shows Sign Of Life
LifeMD Appoints William J. Febbo to its Board of Directors
LifeMD, Inc. Reports First Quarter 2023 Results; Record Revenues and Adjusted EBITDA
LifeMD and HealthWarehouse.com Partner in Exclusive Telehealth Agreement
LifeMD, Inc. to Announce First Quarter 2023 Financial Results on May 12, 2023
Source: https://incomestatements.info
Category: Stock Reports